Cytosorbents Corp (CTSO) Stock: Financials, SEC Filings & Ownership
Cytosorbents Corp (CTSO) reported trailing twelve-month revenue of $37.2M (up 3.1% year on year) and net income of -$18.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Market cap: $16.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 16.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 8 days
Price
The price chart — with earnings days, unusual moves, 8-Ks and insider trades marked — opens with a free account.
Our verdict
Five questions and why →Our read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysTiming
Today's price conditions
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysAnalyst note
Our written read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysDividends & buybacks
yield — · payout —No dividends or buybacks in the filed statements.
Performance
price return · vs. S&P 500 and the sector| Window | CTSO | vs. S&P 500 | vs. sector |
|---|---|---|---|
| 1 month | +22.6% | +23.5% | +17.0% |
| 3 months | -26.8% | -29.6% | -36.5% |
| 6 months | -58.0% | -64.5% | -82.4% |
| Year to date | -59.8% | -71.1% | -75.1% |
| 1 year | -69.0% | -82.8% | -91.8% |
Cytosorbents Corp — questions
- What does Cytosorbents Corp do?
- Cytosorbents Corp operates in the Medical Instruments & Supplies industry of the Healthcare sector. In its SEC filings it reports 2 business lines: blood purification devices for hospitals (50%), drug removal devices for hospitals (50%). Trailing twelve-month revenue: $37.2 million as of 2026-06-30.
- What is Cytosorbents Corp's revenue?
- $37.2M over the twelve months to 2026-06-30, up 3.1% year on year, from its 10-Q and 10-K filings.
- What is Cytosorbents Corp's market cap?
- $16.6M.
- Who owns Cytosorbents Corp stock?
- 51 institutions reported Cytosorbents Corp shares in 13F filings for the quarter ended 2026-06-30. The largest: Avenir, Neuberger Berman Group (62.6%), Vanguard Capital Management (60.9%).
- When does Cytosorbents Corp report earnings?
- Cytosorbents Corp's next earnings report is expected on 2026-11-03.
- What sector is Cytosorbents Corp in?
- Cytosorbents Corp is in the Healthcare sector, Medical Instruments & Supplies industry.
- Who are Cytosorbents Corp's competitors?
- The nearest listed peers by market cap in Medical Instruments & Supplies: SHOULDER INNOVATIONS, INC. (SI), CARLSMED, INC. (CARL), Embecta Corp. (EMBC), Orchestra BioMed Holdings, Inc. (OBIO), Sanara MedTech Inc. (SMTI).
Every figure on this page comes from Cytosorbents Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
Source filings: FY2025 10-K · FY2024 10-K · FY2023 10-K · FY2022 10-K · FY2021 10-K · balance sheet 10-Q for 2026-06-30
Peers and related: SHOULDER INNOVATIONS, INC. (SI) · CARLSMED, INC. (CARL) · Embecta Corp. (EMBC) · Orchestra BioMed Holdings, Inc. (OBIO) · Sanara MedTech Inc. (SMTI) · All Medical Instruments & Supplies companies
How these figures are read: methodology · EquiReason.